89bio reports third quarter 2021 financial results and provides corporate update

San francisco, nov. 11, 2021 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended september 30, 2021.
ETNB Ratings Summary
ETNB Quant Ranking